Access the full text.
Sign up today, get DeepDyve free for 14 days.
Alexander Sherman, Gabriela Motyckova, K. Fega, D. DeAngelo, G. Abel, D. Steensma, M. Wadleigh, R. Stone, Jane Driver, Jane Driver, Jane Driver (2013)
Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.Leukemia research, 37 9
M. Extermann, I. Boler, R. Reich, G. Lyman, Richard Brown, J. Defelice, R. Levine, E. Lubiner, P. Reyes, F. Schreiber, L. Balducci (2012)
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) scoreCancer, 118
G. Juliusson, P. Antunović, A. Derolf, S. Lehmann, L. Möllgård, D. Stockelberg, U. Tidefelt, A. Wåhlin, M. Höglund (2009)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.Blood, 113 18
(2008)
Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experienceCancer, 112
A. Hurria, K. Togawa, S. Mohile, C. Owusu, H. Klepin, C. Gross, S. Lichtman, A. Gajra, S. Bhatia, V. Katheria, S. Klapper, K. Hansen, R. Ramani, M. Lachs, F. Wong, W. Tew (2011)
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 25
S. Farag, K. Archer, K. Mrózek, A. Ruppert, A. Carroll, J. Vardiman, M. Pettenati, M. Baer, M. Qumsiyeh, Prasad Koduru, Yi Ning, Robert Mayer, Richard Stone, Richard Larson, C. Bloomfield (2006)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.Blood, 108 1
H. Kantarjian, S. O'brien (2010)
Questions regarding frontline therapy of acute myeloid leukemiaCancer, 116
D. Pollyea, J. Zehnder, S. Coutre, J. Gotlib, L. Gallegos, O. Abdel-Wahab, P. Greenberg, Bing Zhang, M. Liedtke, C. Berubé, R. Levine, B. Mitchell, B. Medeiros (2013)
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaHaematologica, 98
S. Faderl, F. Ravandi, Xuelin Huang, G. Garcia-Manero, A. Ferrajoli, Z. Estrov, G. Borthakur, S. Verstovsek, D. Thomas, M. Kwari, H. Kantarjian (2008)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.Blood, 112 5
(2015)
Rare Cancers Ther
H. Serve, U. Krug, R. Wagner, M. Sauerland, A. Heinecke, U. Brunnberg, M. Schaich, O. Ottmann, J. Duyster, H. Wandt, T. Fischer, Aristoteles Giagounidis, A. Neubauer, A. Reichle, W. Aulitzky, R. Noppeney, I. Blau, V. Kunzmann, R. Stuhlmann, A. Krämer, K. Kreuzer, C. Brandts, B. Steffen, C. Thiede, C. Müller-Tidow, G. Ehninger, Wolfgang Berdel (2013)
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 25
W. Blum, S. Schwind, S. Tarighat, S. Geyer, Ann-Kathrin Eisfeld, S. Whitman, A. Walker, R. Klisovic, J. Byrd, R. Santhanam, Hongyan Wang, John Curfman, S. Devine, S. Jacob, C. Garr, C. Kefauver, D. Perrotti, K. Chan, C. Bloomfield, M. Caligiuri, M. Grever, R. Garzon, G. Marcucci (2012)
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Blood, 119 25
(Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015; [Epub ahead of print].)
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015; [Epub ahead of print].Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015; [Epub ahead of print]., Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015; [Epub ahead of print].
S. Alibhai, S. O'Neill, K. Fisher-Schlombs, H. Breunis, Joseph Brandwein, Joseph Brandwein, N. Timilshina, G. Tomlinson, George Tomlinson, H. Klepin, S. Culos-Reed, S. Culos-Reed (2012)
A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy.Leukemia research, 36 10
C. Leith, K. Kopecky, I. Chen, Lisette Eijdems, M. Slovak, T. McConnell, D. Head, J. Weick, M. Grever, F. Appelbaum, C. Willman (1999)
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.Blood, 94 3
B. Löwenberg, R. Zittoun, H. Kerkhofs, U. Jehn, J. Abels, L. Debusscher, C. Cauchie, M. Peetermans, G. Solbu, S. Suciu (1989)
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 9
D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C. Harrison, K. Wheatley, A. Burnett, A. Goldstone (2001)
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.Blood, 98 5
Sara Garrido, John Cooper, John Cooper, Frederick Appelbaum, Frederick Appelbaum, C. Willman, C. Willman, K. Kopecky, K. Kopecky, D. Banker, D. Banker (2001)
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.Leukemia research, 25 1
B. Oran, D. Weisdorf (2012)
Survival for older patients with acute myeloid leukemia: a population-based studyHaematologica, 97
(2014)
Phase II, multicenter, randomized, open label trial of CPX351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60–75 years of age
Kellie Flood, M. Carroll, C. Le, L. Ball, Debbie Esker, D. Carr (2006)
Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 15
E. Stein, M. Tallman, D. Pollyea, I. Flinn, A. Fathi, R. Stone, R. Levine, S. Agresta, D. Schenkein, Hua Yang, Bin Fan, K. Yen, S. Botton (2014)
Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignanciesCancer Research, 74
M. Wetzler, K. Mrózek, J. Kohlschmidt, H. Dombret, H. Döhner, S. Pilorge, U. Krug, A. Carroll, R. Larson, G. Marcucci, W. Hiddemann, T. Büchner, C. Bloomfield (2014)
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classificationHaematologica, 99
G. Garcia-Manero, E. Estey, E. Jabbour, G. Borthakur, T. Kadia, K. Naqvi, R. Levine, Z. Estrov, A. Quintás-Cardama, M. Konopleva, S. Faderl, M. Tanaka, Hui Yang, F. Ravandi, W. Wierda, J. Cortes, P. Boone, H. Kantarjian (2010)
Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other ComorbiditiesBlood, 118
B. Mcclune, D. Weisdorf, T. Pedersen, Gisela Silva, M. Tallman, J. Sierra, J. Dipersio, A. Keating, R. Gale, B. George, Vikas Gupta, T. Hahn, L. Isola, M. Jagasia, H. Lazarus, D. Marks, R. Maziarz, E. Waller, C. Bredeson, S. Giralt (2010)
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
A. Burnett, N. Russell, D. Culligan, Jamie Cavanagh, J. Kell, K. Wheatley, A. Virchis, R. Hills, D. Milligan (2012)
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AMLBritish Journal of Haematology, 158
S. Dubruille, Y. Libert, M. Maerevoet, M. Roos, A. Collard, S. Vandenbossche, N. Meuleman, D. Razavi, D. Bron (2014)
Prognostic Value of Neuro-Psychological and Biological Factors in Clinically Fit Older Patients with Hematological MalignanciesBlood, 124
S. Castaigne, C. Pautas, C. Terré, E. Raffoux, D. Bordessoule, J. Bastie, O. Legrand, X. Thomas, P. Turlure, O. Reman, T. Revel, L. Gastaud, Noémie Gunzburg, N. Contentin, Estelle Henry, J. Marolleau, Ahmad Aljijakli, P. Rousselot, P. Fenaux, C. Preudhomme, S. Chevret, H. Dombret (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studyThe Lancet, 379
M. Hamaker, M. Prins, R. Stauder (2014)
The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review.Leukemia research, 38 3
A. Burnett, N. Russell, A. Hunter, D. Milligan, S. Knapper, K. Wheatley, J. Yin, M. McMullin, Sahra Ali, D. Bowen, R. Hills (2013)
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.Blood, 122 8
J. Lancet, J. Cortes, D. Hogge, M. Tallman, T. Kovacsovics, L. Damon, R. Komrokji, S. Solomon, J. Kolitz, M. Cooper, A. Yeager, A. Louie, E. Feldman (2014)
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.Blood, 123 21
B. Deschler, G. Ihorst, U. Platzbecker, U. Germing, E. März, Marcelo Figuerido, K. Fritzsche, P. Haas, H. Salih, A. Giagounidis, D. Selleslag, B. Labar, T. Witte, P. Wijermans, M. Lübbert (2013)
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcomeHaematologica, 98
A. Quintás-Cardama, F. Ravandi, T. Liu-Dumlao, M. Brandt, S. Faderl, S. Pierce, G. Borthakur, G. Garcia-Manero, J. Cortes, H. Kantarjian (2012)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.Blood, 120 24
(Ravandi F, Faderl S, Cortes JE, et al. Phase 1/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML. Blood. 2011; 118:abstract 3630.)
Ravandi F, Faderl S, Cortes JE, et al. Phase 1/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML. Blood. 2011; 118:abstract 3630.Ravandi F, Faderl S, Cortes JE, et al. Phase 1/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML. Blood. 2011; 118:abstract 3630., Ravandi F, Faderl S, Cortes JE, et al. Phase 1/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML. Blood. 2011; 118:abstract 3630.
Jay Patel, M. Gönen, M. Figueroa, H. Fernandez, Zhuoxin Sun, J. Racevskis, P. Vlierberghe, Igor Dolgalev, S. Thomas, Olga Aminova, K. Huberman, Janice Cheng, A. Viale, N. Socci, A. Heguy, A. Cherry, G. Vance, R. Higgins, R. Ketterling, R. Gallagher, M. Litzow, M. Brink, H. Lazarus, J. Rowe, S. Luger, A. Ferrando, E. Paietta, M. Tallman, A. Melnick, O. Abdel-Wahab, R. Levine (2012)
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.The New England journal of medicine, 366 12
H. Klepin, A. Geiger, J. Tooze, S. Kritchevsky, J. Williamson, L. Ellis, D. Levitan, T. Pardee, S. Isom, B. Powell (2011)
The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous LeukemiaJournal of the American Geriatrics Society, 59
H. Kantarjian, M. Sekeres, V. Ribrag, P. Rousselot, G. Garcia-Manero, E. Jabbour, Kate Owen, P. Stockman, S. Oliver (2013)
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.Clinical lymphoma, myeloma & leukemia, 13 5
R. Schlenk, K. Döhner, J. Krauter, S. Fröhling, A. Corbacioglu, L. Bullinger, Marianne Habdank, D. Späth, M. Morgan, A. Benner, B. Schlegelberger, G. Heil, A. Ganser, H. Döhner (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.The New England journal of medicine, 358 18
R. Maggiore, W. Dale, C. Gross, Tao Feng, W. Tew, S. Mohile, C. Owusu, H. Klepin, S. Lichtman, A. Gajra, R. Ramani, V. Katheria, Laura Zavala, A. Hurria (2014)
Polypharmacy and Potentially Inappropriate Medication Use in Older Adults with Cancer Undergoing Chemotherapy: Effect on Chemotherapy‐Related Toxicity and Hospitalization During TreatmentJournal of the American Geriatrics Society, 62
H. Döhner, M. Lübbert, W. Fiedler, L. Fouillard, A. Haaland, J. Brandwein, S. Leprêtre, O. Reman, P. Turlure, O. Ottmann, C. Müller-Tidow, A. Krämer, E. Raffoux, K. Döhner, R. Schlenk, F. Voß, T. Taube, H. Fritsch, J. Maertens (2014)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.Blood, 124 9
K. Wheatley, C. Brookes, Andrew Howman, A. Goldstone, D. Milligan, A. Prentice, A. Moorman, A. Burnett (2009)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trialsBritish Journal of Haematology, 145
F. Ravandi, S. Faderl, J. Cortes, G. Garcia-Manero, E. Jabbour, P. Boone, T. Kadia, G. Borthakur, W. Wierda, M. Wetzler, P. Venugopal, J. Chiao, H. Kantarjian (2011)
Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,Blood, 118
(Stein E, Tallman MS, Pollya D, et al. Clinical safety and activity in a phase I trial AG-221, a first in class, potent inhibitor of the IDH2-mutant protein in patients with IDH2 mutant positive advanced hematologic malignancies. AACR Annual Meeting. 2014; abstract CT103.)
Stein E, Tallman MS, Pollya D, et al. Clinical safety and activity in a phase I trial AG-221, a first in class, potent inhibitor of the IDH2-mutant protein in patients with IDH2 mutant positive advanced hematologic malignancies. AACR Annual Meeting. 2014; abstract CT103.Stein E, Tallman MS, Pollya D, et al. Clinical safety and activity in a phase I trial AG-221, a first in class, potent inhibitor of the IDH2-mutant protein in patients with IDH2 mutant positive advanced hematologic malignancies. AACR Annual Meeting. 2014; abstract CT103., Stein E, Tallman MS, Pollya D, et al. Clinical safety and activity in a phase I trial AG-221, a first in class, potent inhibitor of the IDH2-mutant protein in patients with IDH2 mutant positive advanced hematologic malignancies. AACR Annual Meeting. 2014; abstract CT103.
H. Kantarjian, E. Jabbour, K. Yee, P. Kropf, C. O'Connell, W. Stock, R. Tibes, D. Rizzieri, K. Walsh, E. Griffiths, G. Roboz, M. Savona, T. Ervin, N. Podoltsev, N. Pemmaraju, N. Daver, G. Garcia-Manero, G. Borthakur, W. Wierda, F. Ravandi, J. Cortes, J. Brandwein, O. Odenike, E. Feldman, W. Chung, S. Naim, G. Choy, P. Taverna, Y. Hao, G. Dimitrov, M. Azab, J. Issa (2013)
First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)Blood, 122
H. Klepin, S. Danhauer, J. Tooze, Kylie Stott, K. Daley, T. Vishnevsky, B. Powell, S. Mihalko (2011)
Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study.Journal of geriatric oncology, 2 1
L. Ries, D. Harkins, Martin Krapcho, A. Mariotto, B. Miller, E. Feuer, L. Clegg, M. Eisner, Marie-Josèphe Horner, N. Howlader, Matthew Hayat, B. Hankey, B. Edwards (2006)
SEER Cancer Statistics Review, 1975-2003
(Dombret H, Preudhomme C, Berthon C, et al. A phase 1 study of the BET-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. 56th Annual Meeting of the American Society of Hematology. Blood. 2014; 124: abstract 117.)
Dombret H, Preudhomme C, Berthon C, et al. A phase 1 study of the BET-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. 56th Annual Meeting of the American Society of Hematology. Blood. 2014; 124: abstract 117.Dombret H, Preudhomme C, Berthon C, et al. A phase 1 study of the BET-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. 56th Annual Meeting of the American Society of Hematology. Blood. 2014; 124: abstract 117., Dombret H, Preudhomme C, Berthon C, et al. A phase 1 study of the BET-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. 56th Annual Meeting of the American Society of Hematology. Blood. 2014; 124: abstract 117.
C. López-Otín, M. Blasco, L. Partridge, M. Serrano, G. Kroemer (2013)
The Hallmarks of AgingCell, 153
B. Löwenberg, G. Ossenkoppele, W. Putten, H. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen‐Lavrencic, M. Lilienfeld-Toal, B. Biemond, E. Vellenga, M. Kooy, L. Verdonck, J. Beck, H. Döhner, A. Gratwohl, T. Pabst, G. Verhoef (2009)
High-dose daunorubicin in older patients with acute myeloid leukemia.The New England journal of medicine, 361 13
S. Kristinsson, A. Derolf, G. Edgren, P. Dickman, M. Björkholm (2009)
Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 12
(Surveillance, Epidemiology, and End Results program: SEER Cancer Statistics Review 1975–2009. http://seer.cancer.gov/archive/csr/1975_2009_pops09/.)
Surveillance, Epidemiology, and End Results program: SEER Cancer Statistics Review 1975–2009. http://seer.cancer.gov/archive/csr/1975_2009_pops09/.Surveillance, Epidemiology, and End Results program: SEER Cancer Statistics Review 1975–2009. http://seer.cancer.gov/archive/csr/1975_2009_pops09/., Surveillance, Epidemiology, and End Results program: SEER Cancer Statistics Review 1975–2009. http://seer.cancer.gov/archive/csr/1975_2009_pops09/.
C. Plesa, Y. Chelghoum, A. Plesa, M. Elhamri, I. Tigaud, M. Michallet, C. Dumontet, X. Thomas (2007)
Prognostic Value of Immunophenotyping in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.Blood, 110
N. Daver, Theresa Dumlao, F. Ravandi, S. Pierce, G. Borthakur, N. Pemmaraju, A. Nazha, S. Faderl, E. Jabbour, G. Garcia-Manero, J. Cortes, H. Kantarjian, A. Quintás-Cardama (2013)
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Clinical lymphoma, myeloma & leukemia, 13 4
H. Klepin, A. Rao, T. Pardee (2014)
Acute myeloid leukemia and myelodysplastic syndromes in older adults.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 24
A. Burnett, R. Hills, A. Hunter, D. Milligan, W. Kell, K. Wheatley, J. Yin, M. McMullin, H. Dignum, D. Bowen, N. Russell (2013)
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparisonLeukemia, 27
H. Becker, G. Marcucci, K. Maharry, M. Radmacher, K. Mrózek, D. Margeson, S. Whitman, Yue-zhong Wu, S. Schwind, P. Paschka, B. Powell, T. Carter, J. Kolitz, M. Wetzler, A. Carroll, M. Baer, M. Caligiuri, R. Larson, C. Bloomfield (2010)
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
H. Klepin, A. Geiger, J. Tooze, S. Kritchevsky, J. Williamson, T. Pardee, L. Ellis, B. Powell (2010)
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.Blood, 121 21
F. Ravandi, M. Alattar, M. Grunwald, M. Rudek, T. Rajkhowa, M. Richie, S. Pierce, N. Daver, G. Garcia-Manero, S. Faderl, A. Nazha, M. Konopleva, G. Borthakur, J. Burger, T. Kadia, S. Dellasala, M. Andreeff, J. Cortes, H. Kantarjian, M. Levis (2013)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.Blood, 121 23
U. Krug, C. Röllig, A. Koschmieder, A. Heinecke, M. Sauerland, M. Schaich, C. Thiede, M. Kramer, J. Braess, K. Spiekermann, T. Haferlach, C. Haferlach, S. Koschmieder, C. Rohde, H. Serve, B. Wörmann, W. Hiddemann, G. Ehninger, W. Berdel, T. Büchner, C. Müller-Tidow (2010)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesThe Lancet, 376
(Dubruille S, Libert Y, Maerevoet M, et al. Prognostic value of neuro-psychological and biological factors in clinically fit older patients with hematological malignancies admitted to receive chemotherapy. Blood. 2014; 124:abstract 2630.)
Dubruille S, Libert Y, Maerevoet M, et al. Prognostic value of neuro-psychological and biological factors in clinically fit older patients with hematological malignancies admitted to receive chemotherapy. Blood. 2014; 124:abstract 2630.Dubruille S, Libert Y, Maerevoet M, et al. Prognostic value of neuro-psychological and biological factors in clinically fit older patients with hematological malignancies admitted to receive chemotherapy. Blood. 2014; 124:abstract 2630., Dubruille S, Libert Y, Maerevoet M, et al. Prognostic value of neuro-psychological and biological factors in clinically fit older patients with hematological malignancies admitted to receive chemotherapy. Blood. 2014; 124:abstract 2630.
G. Ossenkoppele, B. Löwenberg (2015)
How I treat the older patient with acute myeloid leukemia.Blood, 125 5
H. Kantarjian, G. Martinelli, E. Jabbour, A. Quintás-Cardama, K. Ando, J. Bay, A. Wei, Stefanie Gröpper, C. Papayannidis, Kate Owen, L. Pike, N. Schmitt, P. Stockman, A. Giagounidis (2013)
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemiaCancer, 119
R. Stone, D. Berg, S. George, R. Dodge, P. Paciucci, P. Schulman, Edward Lee, J. Moore, B. Powell, M. Baer, C. Bloomfield, C. Schiffer (2001)
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.Blood, 98 3
P. Fenaux, G. Mufti, E. Hellström-Lindberg, V. Santini, N. Gattermann, U. Germing, G. Sanz, A. List, S. Gore, J. Seymour, H. Dombret, J. Backstrom, L. Zimmerman, D. McKenzie, C. Beach, L. Silverman (2010)
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
Heike Kroeger, J. Jelinek, M. Estecio, R. He, Kimie Kondo, W. Chung, Li Zhang, Lanlan Shen, H. Kantarjian, C. Bueso-Ramos, J. Issa (2008)
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.Blood, 112 4
S. Nand, M. Othus, J. Godwin, C. Willman, T. Norwood, D. Howard, S. Coutre, H. Erba, F. Appelbaum (2013)
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.Blood, 122 20
H. Kantarjian, F. Ravandi, S. O'brien, J. Cortes, S. Faderl, G. Garcia-Manero, E. Jabbour, W. Wierda, T. Kadia, S. Pierce, J. Shan, M. Keating, E. Freireich (2010)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.Blood, 116 22
H. Dombret, C. Preudhomme, C. Berthon, E. Raffoux, X. Thomas, N. Vey, C. Gomez-Roca, M. Ethell, K. Yee, F. Bourdel, P. Hérait, M. Michallet, C. Récher, C. Roumier, B. Quesnel (2014)
A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute LeukemiaBlood, 124
C. Gardin, P. Turlure, T. Fagot, X. Thomas, C. Terré, N. Contentin, E. Raffoux, S. Botton, C. Pautas, O. Reman, J. Bourhis, P. Fenaux, S. Castaigne, M. Michallet, C. Preudhomme, T. Revel, D. Bordessoule, H. Dombret (2007)
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.Blood, 109 12
H. Dombret, J. Seymour, A. Butrym, A. Wierzbowska, D. Selleslag, J. Jang, Rajat Kumar, J. Cavenagh, A. Schuh, A. Candoni, C. Récher, I. Sandhu, T. Castillo, H. Al-Ali, G. Martinelli, J. Falantes, R. Noppeney, R. Stone, M. Minden, H. McIntyre, S. Songer, L. Lucy, C. Beach, H. Döhner (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Blood, 126 3
A. Rao, P. Valk, K. Metzeler, C. Acharya, S. Tuchman, M. Stevenson, D. Rizzieri, R. Delwel, C. Buske, S. Bohlander, A. Potti, B. Löwenberg (2009)
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
T-Cell Lymphoma (2006)
47th Annual Meeting of the American Society of Hematology Atlanta, GA.Clinical lymphoma & myeloma, 6 5
A. Burnett, N. Russell, R. Hills, J. Kell, J. Cavenagh, L. Kjeldsen, M. McMullin, P. Cahalin, M. Dennis, L. Friis, Ian Thomas, D. Milligan, R. Clark (2014)
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Blood, 125 25
(2006)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Predictive prognostic models for outcomeCancer, 106
A. Burnett, D. Milligan, A. Prentice, A. Goldstone, M. McMullin, R. Hills, K. Wheatley (2007)
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer, 109
U. Wedding, B. Röhrig, A. Klippstein, H. Fricke, H. Sayer, K. Höffken (2006)
Impairment in functional status and survival in patients with acute myeloid leukaemiaJournal of Cancer Research and Clinical Oncology, 132
S. Alibhai, M. Leach, M. Minden, J. Brandwein (2009)
Outcomes and quality of care in acute myeloid leukemia over 40 yearsCancer, 115
(2014)
J Am Geriatr Soc
(Garcia-Manero G, Estey EH, Jabbour E, et al. Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities. Blood. 2011; 118:abstract 608.)
Garcia-Manero G, Estey EH, Jabbour E, et al. Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities. Blood. 2011; 118:abstract 608.Garcia-Manero G, Estey EH, Jabbour E, et al. Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities. Blood. 2011; 118:abstract 608., Garcia-Manero G, Estey EH, Jabbour E, et al. Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities. Blood. 2011; 118:abstract 608.
T. Hahn, P. McCarthy, A. Hassebroek, C. Bredeson, J. Gajewski, G. Hale, Luis Isola, H. Lazarus, Stephanie Lee, C. LeMaistre, F. Loberiza, R. Maziarz, J. Rizzo, S. Joffe, S. Parsons, N. Majhail (2013)
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 19
(Burnett AK, Russell NH, Hills RK, et al. A randomised comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015; [Epub ahead of print].)
Burnett AK, Russell NH, Hills RK, et al. A randomised comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015; [Epub ahead of print].Burnett AK, Russell NH, Hills RK, et al. A randomised comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015; [Epub ahead of print]., Burnett AK, Russell NH, Hills RK, et al. A randomised comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015; [Epub ahead of print].
C. Röllig, C. Thiede, M. Gramatzki, W. Aulitzky, H. Bodenstein, M. Bornhäuser, U. Platzbecker, R. Stuhlmann, U. Schuler, S. Soucek, M. Kramer, B. Mohr, U. Oelschlaegel, F. Stölzel, M. Bonin, M. Wermke, H. Wandt, G. Ehninger, M. Schaich (2010)
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.Blood, 116 6
A. Burnett, N. Russell, R. Hills, J. Kell, S. Freeman, L. Kjeldsen, A. Hunter, J. Yin, C. Craddock, I. Dufva, K. Wheatley, D. Milligan (2012)
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 32
F. Appelbaum, H. Gundacker, D. Head, M. Slovak, C. Willman, J. Godwin, J. Anderson, S. Petersdorf (2006)
Age and acute myeloid leukemia.Blood, 107 9
E. Jabbour, H. Kantarjian, S. O'brien, J. Cortes, F. Giles, S. Faderl, G. Garcia-Manero, W. Wierda, S. Pierce, J. Shan, E. Estey (2005)
Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.Blood, 106
H. Kantarjian, X. Thomas, A. Dmoszyńska, A. Wierzbowska, G. Mazur, J. Mayer, J. Gau, W. Chou, R. Buckstein, J. Čermák, C. Kuo, A. Oriol, F. Ravandi, S. Faderl, J. Delaunay, D. Lysák, M. Minden, C. Arthur (2012)
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
Matthew Hayat, N. Howlader, M. Reichman, B. Edwards (2007)
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.The oncologist, 12 1
S. Scholl, C. Theuer, V. Scheble, C. Kunert, A. Heller, L. Mügge, H. Fricke, K. Höffken, U. Wedding (2008)
Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemiaEuropean Journal of Haematology, 80
Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents.
Oncology and Therapy – Springer Journals
Published: Jul 4, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.